ClinicalTrials.gov
ClinicalTrials.gov Menu

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA (HAROSA3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02739568
Recruitment Status : Recruiting
First Posted : April 15, 2016
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
Bioprojet

Brief Summary:

The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS.

The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period and further investigating the co-variates or co-medications that affect the pharmacokinetics of pitolisant in the target population.


Condition or disease Intervention/treatment Phase
Excessive Daytime Sleepiness Obstructive Sleep Apnea Drug: Pitolisant (BF2.649) Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
Study Start Date : April 2016
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Pitolisant (BF2.6449
Histamine H3 receptor H3R antagonist/ inverse agonist
Drug: Pitolisant (BF2.649)
Placebo Comparator: Placebo
Placebo
Drug: Placebo



Primary Outcome Measures :
  1. Epworth sleepiness scale (ESS) [ Time Frame: at weeks 12 and 52 ]
    Change from Baseline of ESS


Secondary Outcome Measures :
  1. Percentage of ESS responders [ Time Frame: at weeks 12 and 52 ]
    Percentage of ESS responders

  2. Reduction of sleepiness and sleep episodes on the sleep diary [ Time Frame: at weeks 12 and 52 ]
    Reduction of sleepiness and sleep episodes

  3. Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test [ Time Frame: at weeks 12 and 52 ]
    Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test

  4. European Quality of Life Questionnaire (EQ-5D) [ Time Frame: at weeks 12 and 52 ]
    EQ-5D improvement (mobility, self-care, usual activities, pain/discomfort and anxiety/depression)

  5. Leeds Sleep Evaluation Questionnaire (LSEQ) [ Time Frame: at weeks 12 and 52 ]
    LSEQ improvement (changes in sleep and next morning behaviour during disease/pharmacological investigations)

  6. The Pichot Fatigue Scale [ Time Frame: at weeks 12 and 52 ]
    Pichot Fatigue scale improvement (assessment of the level of discomfort caused by a state of fatigue)

  7. Trail Making Test parts (A and B) [ Time Frame: at weeks 12 and 52 ]
    TMT test improvement

  8. Improvement in Clinical Global Impression (CGI) [ Time Frame: at weeks 12 and 52 ]
    CGI improvement (patient progress and treatment response over time)

  9. Aggregate Z-score of secondary endpoints. [ Time Frame: at weeks 12 and 52 ]
    Aggregate Z-score of secondary endpoints improvement



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and/or female outpatients aged from at least 18 years
  • Patients complaining of EDS refusing to be treated by nCPAP therapy or having been submitted to nCPAP therapy for a minimum period of 3 months, and still complaining of EDS despite the efforts made beforehand to obtain an efficient nCPAP therapy
  • Polysomnography performed (for patients submitted to nCPAP therapy - under nCPAP) between V1 and V2 or during the last 12 months with Apnea-Hypopnea Index (AHI): for patients without nCPAP therapy ≥ 15; for patients under nCPAP therapy less or equal to 10
  • For patients submitted to nCPAP therapy: nCPAP ≥ 4 hours / day (compliance checked on the clock-time counter of the CPAP machine)
  • Mini Mental State Examination (MMSE) ≥ 28
  • Beck Depression Inventory - 13 items (BDI-13) score < 16 and item G (suicidal ideation) of BDI-13 = 0
  • Body Mass Index (BMI )less or equal to 40 kg/m²
  • Epworth Sleepiness Scale (ESS) ≥ 12
  • Female patients with child-bearing potential using a medically accepted method of birth control (i.e. oral contraceptives of normal average dosage) agreeing to continue this method throughout the study, and during the month following treatment discontinuation, being negative to serum pregnancy test performed at the screening visit
  • If specified by the investigator, the patient must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the trial or as long as the investigator deems it clinically indicated. In addition, the patient should be willing to maintain during the study their usual behaviors which could affect their diurnal sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration)
  • Patients having signed and dated the informed consent form

Exclusion Criteria:

  • Patients suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA
  • Patients with co-existing narcolepsy (ICSD 2005), judged on clinical criteria
  • Patients with sleep debt not due to OSA (according to the physician' s judgment)
  • Patients with non-respiratory sleep fragmentation (restless leg syndrome…)
  • Shift work, professional drivers

    • Refusal from the patient to stop any current therapy for EDS or predictable risk for the patient to stop the therapy
    • Patients suffering from a psychiatric disease
    • Acute or chronic disease preventing the improvement assessment, e.g. severe chronic obstructive pulmonary disease (COPD)
    • Current or recent (within one year) history of drug, alcohol, narcotic or other substance abuse or dependence
    • Any significant serious abnormality of the cardiovascular system, e.g. recent myocardial infarction, angina, hypertension or dysrhythmias (within the previous 6 months), Electrocardiogram Fridericia corrected QT interval higher than 450 ms, history of left ventricular hypertrophy or mitral valve prolapse
    • Severe co-morbid medical or biological conditions that may jeopardize study participation at the discretion of the investigator (particularly in the cardiovascular system and the instable diabetes)
    • Positive serology tests (HIV, HCV and HBsAg)
    • Pregnant or breast-feeding women
    • Women with child-bearing potential and no efficient birth-control method
    • Patients unable to understand the study protocol
    • Patients with suspected or known hypersensitivity to study medication
    • Patients with a dominant arm deficiency impeding the achievement of the tests
    • Patients using a prohibited medication
    • Congenital galactose poisoning, glucose and galactose malabsorption, deficit in lactase
    • Patients participating in another study or being in a follow-up period for another study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02739568


Contacts
Contact: Patricia RODRIGUEZ +33147036631 p.rodriguez@bioprojet.com
Contact: Djamel BIR +33147036653 d.bir@bioprojet.com

Locations
Bulgaria
Specialised Hospital for Active Treatment of pneumo-phthisiatric diseases - Burgas" EOOD, Pneumology ward Recruiting
Burgas, Bulgaria, 8000
Contact: Zdravka Karamyan-Doncheva, MD         
Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EOOD Recruiting
Kozloduy, Bulgaria, 3320
Contact: Rumen Tiholov, MD         
Multiprofile Hospital for Active Treatment "Sv. Paraskeva" OOD Active, not recruiting
Pleven, Bulgaria, 5800
University Multiprofile Hospital for Active Treatment "Kaspela" EOOD Clinic of thoracic surgery Recruiting
Plovdiv, Bulgaria, 5000
Contact: Stanislav Kartev, MD         
University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD Recruiting
Sofia, Bulgaria, 1432
Contact: Ognian Georgiev, professor         
Macedonia, The Former Yugoslav Republic of
Hospital of Skopje Recruiting
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Contact: Dejan Dokic, MD         
Sponsors and Collaborators
Bioprojet

Responsible Party: Bioprojet
ClinicalTrials.gov Identifier: NCT02739568     History of Changes
Other Study ID Numbers: P15 13/ BF2.649
First Posted: April 15, 2016    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018

Keywords provided by Bioprojet:
EDS
OSA

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases